News
-
-
-
PRESS RELEASE
Data published in Nature Communications highlights unique Mechanism of Action of Alpibectir in combination with Ethionamide (AlpE)
BioVersys AG and partners publish pre-clinical development data of AlpE in Nature Communications, showcasing unique Mechanism of Action targeting drug-resistance in tuberculosis -
-
-
-
-
-
PRESS RELEASE
Communiqué de presse : Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants
Dupixent de Sanofi et Regeneron approuvé pour l'urticaire chronique spontanée (UCS) chez les jeunes enfants par l'UE. Nouvelle approbation élargit l'indication du médicament pour les enfants dès 2 ans -
PRESS RELEASE
Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
Sanofi and Regeneron's Dupixent approved in the EU for young children with chronic spontaneous urticaria, expanding treatment options to address type 2 inflammation
